AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

RIFAXIMINE

9 registrations across 3 African markets— 3 active

Markets with RIFAXIMINE

Recent registrations

Brand / ProductMarketHolderStatusExpires
DIARIX
Comprimé pelliculé / 200 mg
🇹🇳TunisiaGALPHARMAexpiredJun 2019
RIFIXINE 200
Comprimé pelliculé / 200 mg
🇹🇳TunisiaTAHA PHARMAexpiredApr 2017
DIARIX
Comprimé pelliculé / 200 mg
🇹🇳TunisiaGALPHARMAexpiredJul 2015
RIFIXINE 200
Comprimé pelliculé / 200 mg
🇹🇳TunisiaTAHA PHARMAexpiredJan 2015
NORMIX
Comprime enrobé / 200 MG
🇹🇳TunisiaALFASIGMA S.p.A.expiredNov 2001
NORMIX
Suspension buvable / 2 %
🇹🇳TunisiaALFASIGMA S.p.A.expiredNov 2001
RIFIXINE
comprimé pelliculé / 200 mg
🇸🇳SenegalTAHA PHARMAactive
NORMIX
comprimé pelliculé / 200 mg
🇸🇳SenegalALFA ASSERMANNactive
NORMIX 200MG COMPRIME BOITE DE 12🇨🇮Côte d'IvoireALFASIGMA S.P.Aactive

RIFAXIMINE in Africa — Regulatory Overview

RIFAXIMINE is registered across 3 African markets with 9 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Tunisia, Senegal, Côte d'Ivoire. AfricaRegulatory refreshes this data daily from official government sources.

Of the 9 registrations, 3 (33%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.